Hyperfine, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first...
Brain
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
LAS VEGAS, NV / ACCESSWIRE / November 16, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a...
REMORY, a Supplement Known for Containing Plasmalogens, Which Are Recognized for Their Role in Preventing Cognitive Decline, Now Available in the United States
REMORY: Elevate Cognitive Health with Unique Sea Squirt-Derived Plasmalogens. Now in the U.S., this Japanese-Innovated Supplement Combines EPA, DHA, and...
Montecito Names Tony Holland Head of Sales for New Provider Platform
Healthcare technology veteran leads team connecting medical community to growing suite of physician-focused products and servicesNASHVILLE, Tenn.--(BUSINESS WIRE)--Montecito Medical has...
FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023
TORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
MSU Research for Halberd to Transcend the TBI Nasal SprayJACKSON CENTER, PA / ACCESSWIRE / November 15, 2023 / Halberd...
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment...
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
Results From Landmark Study Published in Brain JournalCollaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene...
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues...
Acentra Health Awarded New Contract Supporting Utilization Management and Assessment Services for West Virginia Medicaid
Award builds on company’s 23-year state partnership to accelerate better health outcomes for Medicaid membersMCLEAN, Va., Nov. 14, 2023 (GLOBE...
Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics
Providence, Rhode Island, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company working to accelerate...
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage...
Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer
Amydis Novel Tracer Utilizes an Affordable, Accessible, Non-Invasive Approach as part of a Standard Office VisitSAN DIEGO, Nov. 14, 2023...
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Phase 1 clinical study of GT-02287 initiated; dosing escalation on scheduleBETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics,...
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target...
Zeto Exhibits at Neuroscience 2023 and Will Sponsor EEG Clinical Trials
SANTA CLARA, CA / ACCESSWIRE / November 13, 2023 / Zeto, Inc., an innovative EEG brain monitoring company, is excited...
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with...
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE...
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June,...
Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression
Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany,...